miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation

被引:143
作者
Boni, Valentina [1 ,2 ]
Bitarte, Nerea [2 ]
Cristobal, Ion [3 ]
Zarate, Ruth [2 ]
Rodriguez, Javier [4 ]
Maiello, Evaristo [1 ]
Garcia-Foncillas, Jesus [2 ,4 ]
Bandres, Eva [2 ]
机构
[1] Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy
[2] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, Lab Pharmacogenom, Pamplona 31008, Spain
[3] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, Genet Lab, Pamplona 31008, Spain
[4] Univ Navarra Clin, Dept Oncol, Pamplona, Spain
关键词
HUMAN CANCER-CELLS; THYMIDYLATE SYNTHASE; COLORECTAL-CANCER; COLON-CANCER; RECTAL-CANCER; DIHYDROFOLATE-REDUCTASE; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; MOUSE FIBROBLASTS; PROGNOSTIC VALUE;
D O I
10.1158/1535-7163.MCT-10-0061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thymidylate synthase (TYMS) is a target of the most widely used chemotherapeutic agents against gastrointestinal malignancies, the fluoropyrimidine-based therapy. TYMS expression levels have been identified as predictive biomarkers for 5-fluoruracil (FU) response in colorectal cancer, but their clinical utility remains controversial. The complexity of fluoropyrimidine response must require more mechanisms that currently have not been completely elucidated. In this context, microRNAs (miRNA) may play a role in modulating chemosensitivity. By carrying out an in silico analysis coupled to experimental validation, we detected that miR-192 and miR-215 target TYMS expression in colorectal cancer cell lines. However, downregulation of TYMS by these miRNAs does not sensitize colorectal cancer cell lines to FU treatment. The overexpression of miR192/215 significantly reduces cell proliferation by targeting cell cycle progression. This effect was partially associated with p53 status, because reduction of cell proliferation and cell cycle arrest was associated with p21 and p27 induction. The decrease of S-phase cells by these miRNAs mitigates the effects of S phase-specific drugs and suggests that other mechanisms different from TYMS overexpression are essential to direct FU resistance. Finally, ectopic expression of miR-192/215 might have stronger impact to predict FU response than TYMS inhibition. Prospective studies to elucidate the role of these miRNAs as predictive biomarkers to FU are necessary. Mol Cancer Ther; 9(8); 2265-75. (C) 2010 AACR.
引用
收藏
页码:2265 / 2275
页数:11
相关论文
共 41 条
  • [1] ASCHELE C, 1992, CANCER RES, V52, P1855
  • [2] BERGER SH, 1985, MOL PHARMACOL, V28, P461
  • [3] Boku N, 1998, CLIN CANCER RES, V4, P1469
  • [4] p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest
    Braun, Christian J.
    Zhang, Xin
    Savelyeva, Irina
    Wolff, Sonja
    Moll, Ute M.
    Schepeler, Troels
    Orntoft, Torben F.
    Andersen, Claus L.
    Dobbelstein, Matthias
    [J]. CANCER RESEARCH, 2008, 68 (24) : 10094 - 10104
  • [5] Limits to Thymidylate Synthase and TP53 Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence
    Brody, Jonathan R.
    Hucl, Tomas
    Costantino, Christina L.
    Eshleman, James R.
    Gallmeier, Eike
    Zhu, Heng
    van der Heijden, Michiel S.
    Winter, Jordan M.
    Wikiewicz, Agnieszka K.
    Yeo, Charles J.
    Kern, Scott E.
    [J]. CANCER RESEARCH, 2009, 69 (03) : 984 - 991
  • [6] Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy
    Cascinu, S
    Graziano, F
    Valentini, M
    Catalano, V
    Giordani, P
    Staccioli, MP
    Rossi, C
    Baldelli, AM
    Grianti, C
    Muretto, P
    Catalano, G
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (02) : 239 - 244
  • [7] CHU E, 1990, CANCER RES, V50, P5834
  • [8] CHU E, 1993, MOL PHARMACOL, V43, P527
  • [9] CLARK JL, 1987, CANCER TREAT REP, V71, P261
  • [10] CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL
    DIASIO, RB
    HARRIS, BE
    [J]. CLINICAL PHARMACOKINETICS, 1989, 16 (04) : 215 - 237